The company reported ₤50.5 million for the year ended Sept. 30, 2012, up just slightly from the ₤49.7 million reported for the previous year. The company includes an Invibio biomaterial solutions business line.
More Articles on Orthopedic Devices:
13 Spine Devices Receive FDA 510(k) Clearance in September
How A Facility Implements Generic Orthopedic Implants
Pinnacle Spine Group Wins FDA Approval for Direct Lateral System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.